Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the MiaPaCa2 flank xenograft model

Julio Cárdenas-Rodríguez, Yuguo Li, Jean Philippe Galons, Heather Cornnell, Robert J. Gillies, Mark D. Pagel, Amanda F. Baker

Research output: Contribution to journalArticle

Abstract

TH-302, a hypoxia-activated anticancer prodrug, was evaluated for antitumor activity and changes in dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) in a mouse model of pancreatic cancer. TH-302 monotherapy resulted in a significant delay in tumor growth compared to vehicle-treated controls. TH-302 treatment was also associated with a significant decrease in the volume transfer constant (Ktrans) compared to vehicle-treated controls 1 day following the first dose measured using DCE-MRI. This early decrease in Ktrans following the first dose as measured is consistent with selective killing of the hypoxic fraction of cells which are associated with enhanced expression of hypoxia inducible transcription factor-1 alpha that regulates expression of permeability and perfusion factors including vascular endothelial growth factor-A. No changes were observed in DW-MRI following treatment with TH-302, which may indicate that this technique is not sensitive enough to detect changes in small hypoxic fractions of the tumor targeted by TH-302. These results suggest that changes in tumor permeability and/or perfusion may be an early imaging biomarker for response to TH-302 therapy.

Original languageEnglish (US)
Pages (from-to)1002-1009
Number of pages8
JournalMagnetic Resonance Imaging
Volume30
Issue number7
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Fingerprint

Prodrugs
Biomarkers
Heterografts
Magnetic resonance
Imaging techniques
Tumors
Diffusion Magnetic Resonance Imaging
Transcription factors
Permeability
Perfusion
Hypoxia-Inducible Factor 1
Neoplasms
Pancreatic Neoplasms
Vascular Endothelial Growth Factor A
TH 302
Hypoxia
Transcription Factors
Magnetic Resonance Imaging
Growth

Keywords

  • Diffusion-weighted MRI
  • Dynamic contrast-enhanced MRI
  • TH-302
  • Tumor hypoxia

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging
  • Biomedical Engineering

Cite this

Cárdenas-Rodríguez, J., Li, Y., Galons, J. P., Cornnell, H., Gillies, R. J., Pagel, M. D., & Baker, A. F. (2012). Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the MiaPaCa2 flank xenograft model. Magnetic Resonance Imaging, 30(7), 1002-1009. https://doi.org/10.1016/j.mri.2012.02.015

Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the MiaPaCa2 flank xenograft model. / Cárdenas-Rodríguez, Julio; Li, Yuguo; Galons, Jean Philippe; Cornnell, Heather; Gillies, Robert J.; Pagel, Mark D.; Baker, Amanda F.

In: Magnetic Resonance Imaging, Vol. 30, No. 7, 01.09.2012, p. 1002-1009.

Research output: Contribution to journalArticle

Cárdenas-Rodríguez, J, Li, Y, Galons, JP, Cornnell, H, Gillies, RJ, Pagel, MD & Baker, AF 2012, 'Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the MiaPaCa2 flank xenograft model', Magnetic Resonance Imaging, vol. 30, no. 7, pp. 1002-1009. https://doi.org/10.1016/j.mri.2012.02.015
Cárdenas-Rodríguez, Julio ; Li, Yuguo ; Galons, Jean Philippe ; Cornnell, Heather ; Gillies, Robert J. ; Pagel, Mark D. ; Baker, Amanda F. / Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the MiaPaCa2 flank xenograft model. In: Magnetic Resonance Imaging. 2012 ; Vol. 30, No. 7. pp. 1002-1009.
@article{49b2cee9ae984802bb80cbbd26007e1d,
title = "Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the MiaPaCa2 flank xenograft model",
abstract = "TH-302, a hypoxia-activated anticancer prodrug, was evaluated for antitumor activity and changes in dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) in a mouse model of pancreatic cancer. TH-302 monotherapy resulted in a significant delay in tumor growth compared to vehicle-treated controls. TH-302 treatment was also associated with a significant decrease in the volume transfer constant (Ktrans) compared to vehicle-treated controls 1 day following the first dose measured using DCE-MRI. This early decrease in Ktrans following the first dose as measured is consistent with selective killing of the hypoxic fraction of cells which are associated with enhanced expression of hypoxia inducible transcription factor-1 alpha that regulates expression of permeability and perfusion factors including vascular endothelial growth factor-A. No changes were observed in DW-MRI following treatment with TH-302, which may indicate that this technique is not sensitive enough to detect changes in small hypoxic fractions of the tumor targeted by TH-302. These results suggest that changes in tumor permeability and/or perfusion may be an early imaging biomarker for response to TH-302 therapy.",
keywords = "Diffusion-weighted MRI, Dynamic contrast-enhanced MRI, TH-302, Tumor hypoxia",
author = "Julio C{\'a}rdenas-Rodr{\'i}guez and Yuguo Li and Galons, {Jean Philippe} and Heather Cornnell and Gillies, {Robert J.} and Pagel, {Mark D.} and Baker, {Amanda F.}",
year = "2012",
month = "9",
day = "1",
doi = "10.1016/j.mri.2012.02.015",
language = "English (US)",
volume = "30",
pages = "1002--1009",
journal = "Magnetic Resonance Imaging",
issn = "0730-725X",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the MiaPaCa2 flank xenograft model

AU - Cárdenas-Rodríguez, Julio

AU - Li, Yuguo

AU - Galons, Jean Philippe

AU - Cornnell, Heather

AU - Gillies, Robert J.

AU - Pagel, Mark D.

AU - Baker, Amanda F.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - TH-302, a hypoxia-activated anticancer prodrug, was evaluated for antitumor activity and changes in dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) in a mouse model of pancreatic cancer. TH-302 monotherapy resulted in a significant delay in tumor growth compared to vehicle-treated controls. TH-302 treatment was also associated with a significant decrease in the volume transfer constant (Ktrans) compared to vehicle-treated controls 1 day following the first dose measured using DCE-MRI. This early decrease in Ktrans following the first dose as measured is consistent with selective killing of the hypoxic fraction of cells which are associated with enhanced expression of hypoxia inducible transcription factor-1 alpha that regulates expression of permeability and perfusion factors including vascular endothelial growth factor-A. No changes were observed in DW-MRI following treatment with TH-302, which may indicate that this technique is not sensitive enough to detect changes in small hypoxic fractions of the tumor targeted by TH-302. These results suggest that changes in tumor permeability and/or perfusion may be an early imaging biomarker for response to TH-302 therapy.

AB - TH-302, a hypoxia-activated anticancer prodrug, was evaluated for antitumor activity and changes in dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) in a mouse model of pancreatic cancer. TH-302 monotherapy resulted in a significant delay in tumor growth compared to vehicle-treated controls. TH-302 treatment was also associated with a significant decrease in the volume transfer constant (Ktrans) compared to vehicle-treated controls 1 day following the first dose measured using DCE-MRI. This early decrease in Ktrans following the first dose as measured is consistent with selective killing of the hypoxic fraction of cells which are associated with enhanced expression of hypoxia inducible transcription factor-1 alpha that regulates expression of permeability and perfusion factors including vascular endothelial growth factor-A. No changes were observed in DW-MRI following treatment with TH-302, which may indicate that this technique is not sensitive enough to detect changes in small hypoxic fractions of the tumor targeted by TH-302. These results suggest that changes in tumor permeability and/or perfusion may be an early imaging biomarker for response to TH-302 therapy.

KW - Diffusion-weighted MRI

KW - Dynamic contrast-enhanced MRI

KW - TH-302

KW - Tumor hypoxia

UR - http://www.scopus.com/inward/record.url?scp=84863999020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863999020&partnerID=8YFLogxK

U2 - 10.1016/j.mri.2012.02.015

DO - 10.1016/j.mri.2012.02.015

M3 - Article

C2 - 22554971

AN - SCOPUS:84863999020

VL - 30

SP - 1002

EP - 1009

JO - Magnetic Resonance Imaging

JF - Magnetic Resonance Imaging

SN - 0730-725X

IS - 7

ER -